SITE Centers (US:SITC) Globenewswire·2025-11-07 12:30Core Insights - BriaCell Therapeutics Corp. is presenting strong evidence of immune system engagement and anti-cancer activity of its Bria-OTS+ platform at the Society for Immunotherapy of Cancer Annual Meeting [1][2] Preclinical Findings - Bria-OTS+ demonstrates fast-acting and potent anti-cancer immune system activation, inducing coordinated innate and adaptive immune responses to kill cancer cells [3][7] - The platform produces sustained and durable anti-cancer immune responses, potentially leading to prolonged clinical benefits for patients [4][6] - Positive results from lead candidates Bria-BRES+ (breast cancer) and Bria-PROS+ (prostate cancer) indicate broad applicability of the Bria-OTS+ platform across multiple solid tumor indications [5][7] Platform Overview - Bria-OTS+ is an advanced immunotherapy platform, enhancing the previous Bria-OTS™ version, designed to express multiple immune-activating cytokines and co-stimulatory molecules [6][8] - The platform's unique mechanism of action supports the development of personalized cancer immunotherapies, with planned clinical trials for Bria-BRES+ and Bria-PROS+ [2][6]